Form 4: Acrivon Therapeutics Executive Sells Shares

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, reported a transaction involving the sale of 404 shares of common stock.

Summary

• Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, Inc., reported a transaction on May 14, 2026.
• The transaction involved the disposal of 404 shares of common stock.
• The shares were disposed of at a price of $1.92 per share.
• Following this transaction, Gamelin beneficially owns 14,408 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, despite the stated reason of tax withholding. The sale of shares by an executive can sometimes be perceived as a lack of confidence, even if it's a routine transaction.

Negatives

• A company executive sold shares, which could be interpreted negatively by the market, although the reason provided is tax withholding.

Risks

• The filing does not explicitly mention any risks.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling, even for tax withholding purposes, can sometimes lead to short-term market scrutiny for biotechnology companies like Acrivon Therapeutics, which often rely on investor confidence for funding research and development.

Stakeholder Impact

• Shareholders: May view the executive's sale of shares with caution, potentially impacting short-term stock sentiment, despite the tax withholding explanation.

Next Steps

• The filing itself does not outline specific next steps for the company.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Sale, Erick Gamelin, Chief Development Officer, Beneficial Ownership